Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tirzepatide Use on Muscle and Vascular Function Among Obese Older Adults
NCT06811324Phase 2Recruiting
- Sponsor
- UT Health San Antonio
- Start
- Apr 2026
- Primary completion
- Apr 2027
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tirzepatide in obesity, sponsored by UT Health San Antonio. Primary endpoints: Appendicular lean muscle mass at 6 months, Muscle Strength at 6 months and 1 more. Started Apr 2026; status: recruiting.
02
Drugs
03
Conditions
obesity
Beyond the preview
Go deeper on NCT06811324.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06811324.